CoChat
Sign Up
Cited by 19Substance Abuse Treatment and OutcomesAttention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on Behavior

Ibudilast may improve attention during early abstinence from methamphetamine

Birath, J. Brandon, Briones, Marisa, Amaya, Stephanie, Shoptaw, Steven, Swanson, Aimee-Noelle, Tsuang, John, Furst, Benjamin, Heinzerling, Keith +4 more·2017·Drug and Alcohol Dependence
DOI 10.1016/j.drugalcdep.2017.05.016
Open this paper in CoChat — free account

Abstract

Background Inattention is a deficit related to instilling abstinence from methamphetamine (MA) dependence. This study aimed to determine whether ibudilast (IB; 50mg bid) improves attentional abilities compared to placebo during early abstinence from MA dependence.Methods Attention was assessed in 11 MA-dependent non-treatment seeking participants in a phase IB safety-interaction trial. The Conners' Continuous Performance Test-II (CPT-II), a measure of sustained attention and response inhibition, was administered at baseline and on day 22, 48h post a MA challenge under placebo (P; n=6) or IB 50mg bid (n=5). Group differences were compared using Mann-Whitney U Tests. Groups were similar at baseline in premorbid intellectual functioning, attention deficit hyperactivity symptom scores, impulsivity ratings, and education level, but differed in age. Demographically corrected T-scores for CPT-II performances were utilized.Results Although no group differences in sustained attention existed at baseline, at follow-up, the IB group (Mdn=44.4) showed reduced variability in response times compared with the P group (Mdn=69.9), U=0.00, z=-2.74, p=.006, r=.83. The IB group (Mdn=45.8) also gave fewer perseverative responses than the P group (Mdn=67.0), U=2.00, z=-2.50, p=.01, r=.75. No other significant differences were observed.Conclusions Findings suggest that IB may have a protective effect on sustained attention during early abstinence from MA dependence. This may guide thinking about mechanism of action should IB demonstrate efficacy as a treatment for MA dependence.

Integrity signals

Registry

Crossref · 10.1016/j.drugalcdep.2017.05.016

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Five days of 100 mg ibudilast produced significant improvement in attention tasks over placebo.

    “As well, five days of 100mg the phosphodiesterase inhibitor, ibudilast, produced significant improvement in attention tasks over placebo (66).”

    From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [66]

  • In a randomized placebo-controlled pilot trial of ibudilast for psychostimulant withdrawal, ibudilast significantly reduced variability in response time to an attention task compared to placebo.

    “Significantly reduced variability in response time to an attention task compared to placebo.”

    From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Birath, B. et al., 2017

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Birath, J. B., Briones, M., Amaya, S., Shoptaw, S., Swanson, A.-N., Tsuang, J., Furst, B., Heinzerling, K., Obermeit, L., Maes, L., McKay, C., & Wright, M. J.
Affiliations
University of California, Los Angeles (US)
Corresponding author
Birath, J. Brandon
ORCID
Venue
Drug and Alcohol Dependence
Publisher
Elsevier BV
Published
2017-09
Volume
178
Pages
386-390
ISSN
0376-8716 (ISSN-L)
DOI
10.1016/j.drugalcdep.2017.05.016
OpenAlex
W2680544593
Cited by
19
References
41
Citations by year
2025: 1 · 2023: 5 · 2022: 3 · 2021: 1 · 2020: 6 · 2019: 2 · 2018: 1
FWCI
1.94
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Drug and Alcohol Dependence (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
ibudilast, methamphetamine dependence, abstinence, sustained attention, response inhibition, inattention, impulsivity
MeSH terms
Attention, Humans, Impulsive Behavior, Indolizines, Methamphetamine, Pyrazoles, Pyridines, Reaction Time, Amphetamine-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review